�ڰ�������

�ڰ������� and BluMaiden Biosciences Pte. Ltd. (“BluMaiden BioSciences”) Form Strategic Collaboration to Introduce Novel Insights into Clinical Trials

�ڰ������� Completes $19 Million Second Close of Series C Funding Led by Oppenheimer & Co. Inc. (“Oppenheimer”)

�ڰ������� Completes $36 Million First Close of Series C Funding Led by Oppenheimer Holdings

Leading Singaporean Diagnostic Center Increases MRI Capacity to Expand Patient Access to �ڰ�������’s LiverMultiScan

�ڰ������� and Nuance Collaborate to Scale Access to AI-Enabled Integrated Digital Care Platforms to Improve Patient Care for Metabolic Disease

FDA awards �ڰ������� major grant for the qualification of its noninvasive diagnostic biomarker to reduce liver biopsy in drug trials

LiverMultiScan shown to be a cost-effective alternative to liver biopsies for monitoring patients with autoimmune hepatitis

FDA Grants Clearance to �ڰ�������’s CoverScan – A New Platform-Based Tool to Assess Multiple Organs in One MRI Scan

LiverMultiScan® detected earlier stages of treatable disease in patients with autoimmune hepatitis to allow tailored treatment